The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5

por Schey, Steve, Montero, Luis Felipe Casado, Stengel-Tosetti, Chloe, Gibson, Craig J., Dhanasiri, Sujith
Publicado 2017

Risk of relapse of multiple myeloma following kidney transplantation

por Shah, Sapna, Ibrahim, Maria, Delaney, Michael, Schey, Steve, Bygrave, Ceri, Streetly, Matthew, Benjamin, Reuben
Publicado 2019

Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Cur...

por Kikuchi, Hugh, Amofa, Eunice, Mcenery, Maeve, Schey, Steve Arthur, Ramasamy, Karthik, Farzaneh, Farzin, Calle, Yolanda
Publicado 2023

Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods

por Ramsenthaler, Christina, Gao, Wei, Siegert, Richard J., Schey, Steve A., Edmonds, Poly M., Higginson, Irene J.
Publicado 2017

The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma

por Davies, Joanna M., Osborne, Thomas R., Edmonds, Polly M., Schey, Steve A., Devereux, Steve, Higginson, Irene J., Ramsenthaler, Christina
Publicado 2017